VYJUVEK (beremagene geperpavec-svdt)

Medical Administration – Office Administered

Diagnosis considered for coverage:
  • Wound care in dystrophic epidermolysis bullosa Indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
     
Coverage Criteria:

 

For diagnosis of wound care in dystrophic epidermolysis bullosa:
  • Diagnosis of dystrophic epidermolysis bullosa AND
  • Patient has mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene AND
  • Medication is being used for the treatment of wounds AND
  • Patient is 6 months of age or older AND
  • Medication will be applied by a healthcare professional AND
  • Prescribed by or in consultation with a dermatologist AND
  • Wound(s) being treated meet all of the following criteria:
    • Adequate granulation tissue AND
    • Excellent vascularization AND
    • No evidence of active wound infection in the wound being treated AND
    • No evidence or history of squamous cell carcinoma in the wound being treated
 
Reauthorization Criteria:

 

For diagnosis of wound care in dystrophic epidermolysis bullosa:
  • Documentation of positive clinical response (e.g., decrease in wound size, increase in granulation tissue, complete wound closure AND
  • Wound(s) being treated meet all of the following criteria
    • Adequate granulation tissue AND
    • Excellent vascularization AND
    • No evidence of active wound infection in the wound being treated AND
    • No evidence or history of squamous cell carcinoma in the wound being treated
Coverage Duration: 


Initial: 6 months
Reauthorization: 6 months

Dosing: 
For diagnosis of wound care in dystrophic epidermolysis bullosa:
  • B-VEC is applied once weekly by a healthcare professional in a healthcare facility or in the home setting. 
  • Maximum dosing is determined by age. 
    • For patients aged 6 months to < 3 years, the maximum weekly volume of B-VEC is 0.8 mL; for patients ≥ 3 years, the maximum weekly volume of B-VEC is 1.6 mL.
  • The dose per wound is determined by the surface area of the wound and ranges from 0.2 mL to 0.6 mL
     
Authorization is not covered for the following:


The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
 

Additional Information: 
  • Orphan Drug, Rare Pediatric Disease, and Fast Track designations and underwent Priority Review
  • Manufacturer was granted a rare pediatric disease priority review voucher which entitles the manufacturer to priority review of another product or to sell the voucher to another sponsor
  • B-VEC gel is prepared by the pharmacy by mixing Vyjuvek biological suspension into the excipient gel for use within 8 hours of application if stored at room temperature (20° to 25°C [68° to 77°F]) or within 48 hours if stored in the refrigerator (2º to 8ºC [35.6º to 46.4ºF]).
  • B-VEC gel should be applied in droplets spaced evenly within the wound, approximately 1 cm by 1 cm apart. The droplet pattern should loosely resemble a grid. Wounds should have non-adherent hydrophobic dressing placed atop the B-VEC gel droplets then covered by a standard dressing. Wound dressing should not be changed within 24 hours after B-VEC application
     
Policy Updates:
  • 3/1/2024 (policy effective date)- New Vyjuvek Criteria (P&T 2/20/2024) (P&T meeting February) 
References:
  • Vyjuvek Prescribing Information. Krystal Biotech, Inc. Pittsburgh, PA. May 2023. 
  • Guide SV, Gonzalez ME, Ba?c? IS, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med 2022;387:2211-9. DOI: 10.1056/NEJMoa2206663 
  • Vyjuvek. IBM Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Accessed Nov. 28, 2023. http://www.micromedexsolutions.com.
     

 

 

 

 

 

Last review date: March 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone